Home ›
Drugs ›
Lansoprazole ›
FDA recalls
Lansoprazole
FDA recalls
5 rows
Summary of public sources, not medical advice. This page is an automated summary of public information from the FDA, the National Library of Medicine (DailyMed) and CMS Medicare data. It has not been reviewed by a doctor or pharmacist, may be incomplete, out of date or wrong, and does not list every use, dose, warning, interaction or side effect. Do not start, stop or change any medicine, or take a pill you cannot identify, based on this page: ask your doctor or pharmacist and read the official label. In an emergency call 911; for possible poisoning call Poison Control at 1-800-222-1222. Use of this page is subject to our Medical and Data Disclaimer and Terms of Use .
Date Company and reason Class
Mar 22, 2022 Dr. Reddy's Laboratories, Inc. Failed Dissolution Specifications; during long term stability testing.Class II · Terminated Dec 2, 2020 Zydus Pharmaceuticals (USA) Inc Failed Dissolution SpecificationsClass II · Terminated Oct 26, 2020 Zydus Pharmaceuticals (USA) Inc Failed Dissolution SpecificationClass II · Terminated Mar 10, 2019 Teva Pharmaceuticals USA Subpotent Drug.Class III · Terminated Jan 29, 2013 Mylan Pharmaceuticals Inc. Presence of Foreign Tablets/Capsules: Bottles of lansoprazole 30 mg delayed-release capsules may contain topiramate 100 mg tablets.Class II · Terminated
← Back to Lansoprazole
Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).